Few areas of medical travel generate as much hope, or as much confusion, as stem cell and regenerative treatments. Clinics in many countries advertise injections for joint pain, autism, neurological disease, sports injuries, aging and more. Prices are often high, testimonials are often moving, and the language of science is everywhere.
This guide does not tell you whether to pursue a particular treatment. It explains what the US Food and Drug Administration says about these products, the harms it has documented, and the specific questions that help separate legitimate research from a sales pitch. It is educational, not medical advice, and it does not evaluate any individual clinic.
What is actually approved
Start with the most important fact, because many marketing materials blur it. The FDA states that the only stem cell products it has approved are blood-forming stem cells derived from umbilical cord blood, and that these are approved only for disorders affecting blood production (FDA (2024)). Established treatments such as bone marrow or stem cell transplants for certain blood cancers sit in the world of specialized hospital medicine, not in the clinics advertising to travelers.
The FDA lists a wide range of products marketed as "regenerative medicine" that require FDA approval before they can be marketed to consumers in the US, including stem cells, stromal vascular fraction, cord blood, amniotic fluid, Wharton's jelly, ortho-biologics and exosomes (FDA (2024)). It specifically notes that such products have not been approved for conditions including autism, macular degeneration, blindness, chronic pain and fatigue, or for neurological, cardiovascular, pulmonary or orthopedic conditions.
A clinic abroad operates under its own country's rules, which may be stricter, looser or simply different. The FDA's position does not govern that clinic. It does tell you which uses have been through rigorous review and which have not, which is exactly what a patient needs to know before paying.
Harms the FDA has described
Unapproved does not just mean "unproven to work." The FDA lists reported and potential harms from unapproved regenerative products (FDA (2024)):
| Type of harm | What it can look like |
|---|---|
| Vision loss | Blindness has been reported |
| Abnormal growth | Tumor formation, or cells growing into unintended tissue types |
| Infection | Bacterial infections, including life-threatening blood infections |
| Contamination | Products contaminated by bacteria, viruses or mold during processing, or not tested for infections such as hepatitis and HIV |
| Neurological events | Reported among adverse events |
| Local and immune reactions | Problems at collection or injection sites; unwanted inflammatory or immune responses |
| Lost opportunity | Treatment failure when approved options existed |
The last item deserves emphasis. For some conditions, the greatest risk of an unproven treatment is not what the injection does, but the time and money spent instead of an effective therapy.
Why travel adds another layer of risk
The CDC's medical tourism guidance notes that drugs, laboratory services and devices abroad may be under less regulatory oversight, that some drugs may be counterfeit or poorly stored, and that marketing websites may not provide full information on facility accreditation or clinician credentials (CDC Yellow Book, 2026 edition). The CDC also highlights that donor-derived infections and less thorough screening of donated tissue are concerns in some forms of medical travel.
Put those together with the risks above and the picture becomes clearer: a regenerative product prepared in a facility you cannot inspect, from a source you cannot verify, injected by someone whose training you have to take on trust, and followed by a flight home before any complication has had time to show itself.
Research versus a paid product
Clinics often use research language: "protocol," "study," "trial," "registered." The FDA offers two useful signals here (FDA (2024)):
- Paying for treatment is a warning sign. The FDA says that charging for these products, or offering them outside a clinical trial, suggests the offer is deceptive and illegal under US rules.
- Registration is not approval. Listing a study on ClinicalTrials.gov, or registering with the FDA, does not mean a product is legally marketed.
Genuine clinical research usually has a defined question, eligibility criteria, an independent ethics review and an informed consent process that clearly explains the treatment is experimental and might not help. Participants are not typically asked to pay large fees for the experimental product itself.
Questions to ask any regenerative clinic
Write these down and ask them before any money changes hands. Record the answers, and notice which ones are answered clearly and which are deflected.
About the product
- Exactly what will be injected, and where does it come from?
- Is it my own tissue, donor tissue or a manufactured product?
- Where is it processed, and how is it tested for contamination and infection?
- Which regulator in this country has authorized it, and for what condition?
- Is it approved by the FDA, or studied under an FDA Investigational New Drug application?
About the evidence and the clinic
- What published, peer-reviewed results support this use for my condition?
- Is this a registered trial with independent ethics review, and can I see the protocol?
- Who performs the procedure, and what is their specialty and license?
- What complications have you seen, and how are they handled?
- What happens if I have a problem after I return home?
The question about the FDA comes straight from the agency's own consumer advice, which suggests asking whether a product is FDA-approved or being studied under an Investigational New Drug application (FDA (2024)).
Marketing patterns that should make you pause
One treatment promoted for a long list of unrelated conditions. Heavy reliance on patient testimonials rather than published results. Claims of "no risk" because the cells are your own. Large upfront fees for a "study." Pressure to book quickly or limited-time pricing. Reluctance to share details with your doctor at home.
The UK NHS checklist for treatment abroad offers a useful test for anything not available at home: check whether it is licensed by the national medicines regulator, approved by the national health technology body, listed in an international clinical trials database, and verified by sources other than the provider (NHS treatment-abroad checklist (2023)). Those are UK-specific bodies, but the principle travels: look for verification that does not come from the clinic itself.
If you still decide to go
Some patients weigh all of this and still choose to proceed, often because they feel conventional options have run out. If that is your decision, you can still reduce avoidable risk:
- Get everything in writing. What product, from what source, at what dose, injected where, by whom, and at what total cost.
- Pay in a way you can trace. Avoid cash-only or untraceable transfers for large sums, and keep every receipt.
- Do not stop existing treatment without discussing it with the doctor who prescribed it.
- Stay long enough to be seen again by the clinic before you fly, rather than leaving the same day.
- Leave with records describing exactly what was administered, so a doctor at home can act quickly if you become unwell.
Involve your own doctor
Many patients considering regenerative treatment abroad have a chronic or serious condition and a specialist at home. Tell them what you are considering, and ask:
- Is there evidence for this approach for my specific condition?
- Are there approved treatments or legitimate clinical trials I have not tried?
- Could this treatment interfere with my current care?
- Would you be willing to see me afterward if something goes wrong?
The CDC's guidance encourages all medical travelers to talk with their primary care clinician well before travel and to disclose every treatment received abroad when they return (CDC Yellow Book, 2026 edition). With regenerative products, that disclosure is especially important, because a doctor treating a later infection or reaction needs to know what was injected.
If you have already had treatment
If you have received a regenerative product abroad and develop fever, worsening pain, swelling or redness at an injection site, changes in vision, or new neurological symptoms, seek medical care promptly and tell the clinician exactly what you received and where. The FDA encourages reporting side effects through its MedWatch program and invites people offered treatment outside an FDA-overseen trial to contact the agency (FDA (2024)).
Bottom line
Regenerative medicine is a real and active area of research, and some approaches may eventually prove useful. Today, though, the FDA's position is clear: beyond cord blood-derived stem cells for blood disorders, these products are not approved, and the agency has documented serious harms from unapproved versions. Traveling to receive one adds regulatory, infection and follow-up risks. The safest path is to ask hard questions, look for verification that does not come from the seller, and involve a doctor who is not trying to sell you anything.
Planning a Medical Trip to Colombia?
Work with credentialed clinics that prioritize patient safety from airport to departure. Get matched with verified providers through our hub.
Get a Free Safety Consultation →Frequently Asked Questions
Are any stem cell treatments approved by the FDA?
According to the FDA, the only stem cell products it has approved are blood-forming stem cells derived from umbilical cord blood, and only for disorders that affect blood production. That does not cover the wide range of conditions for which stem cell or regenerative products are commonly marketed.
If a clinic is listed on ClinicalTrials.gov, does that mean its treatment is legitimate?
Not by itself. The FDA specifically notes that listing a study on ClinicalTrials.gov, or registering with the FDA, does not mean a product is legally marketed. A genuine trial has a defined protocol, independent ethics oversight and informed consent, and is not usually a paid service.
Is it safer if the clinic uses my own cells?
Not automatically. Products made from your own tissue still involve collection, processing and injection steps. The FDA lists contamination during processing, reactions at collection or injection sites, and infections among the possible harms of unapproved regenerative products in general.
What is wrong with paying to join a stem cell study?
The FDA states that charging for these products, or offering them outside a clinical trial, suggests that an offer is deceptive and illegal in the US context. Paying a large fee to be treated is a strong sign you are buying a product, not participating in research.
Should I tell my doctor at home if I had a regenerative treatment abroad?
Yes. The CDC asks medical travelers to disclose all treatments received abroad to their clinicians. Your doctor needs to know what was injected, where and when, so they can recognize a complication and avoid interactions with your other care.
Who can I contact in the US if I am offered one of these treatments?
The FDA invites people offered a regenerative product outside an FDA-overseen clinical trial to contact it, and to report side effects through its MedWatch program. Its consumer page lists the current contact details.